Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic Stem Cell Transplantation Jason Tay, Alan Tinmouth, Dean Fergusson, Lothar Huebsch, David S. Allan Biology of Blood and Marrow Transplantation Volume 13, Issue 2, Pages 206-217 (February 2007) DOI: 10.1016/j.bbmt.2006.09.012 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Flow diagram summarizing the identification process of relevant clinical trials. VOD indicates veno-occlusive disease. Biology of Blood and Marrow Transplantation 2007 13, 206-217DOI: (10.1016/j.bbmt.2006.09.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Forest plots of (A) hepatic veno-occlusive disease (primary outcome) in all studies and (B) pooled estimate of hepatic veno-occlusive disease from randomized trials. CI indicates confidence interval; RR, relative risk. Biology of Blood and Marrow Transplantation 2007 13, 206-217DOI: (10.1016/j.bbmt.2006.09.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Funnel plot to assess publication bias using hepatic veno-occlusive disease as an outcome. Biology of Blood and Marrow Transplantation 2007 13, 206-217DOI: (10.1016/j.bbmt.2006.09.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 4 Forest plots of secondary outcomes. aGVHD indicates acute graft-versus-host disease; CI, confidence interval; OS, overall survival; RCT, randomized controlled trial; RR, relative risk; TRM, transplant-related mortality; UA, ursodeoxycholic acid. Biology of Blood and Marrow Transplantation 2007 13, 206-217DOI: (10.1016/j.bbmt.2006.09.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 5 Point estimate of relative risk of hepatic veno-occlusive disease (HVOD) and 95% confidence interval in the 3 randomized trials comparing ursodeoxycholic acid with no treatment as compared with the proportion of HVOD in the control population. Biology of Blood and Marrow Transplantation 2007 13, 206-217DOI: (10.1016/j.bbmt.2006.09.012) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions